Memorial Sloan Kettering Cancer Center
The purpose of this study is to see how results of nerve tests change in people with urothelial cancer who receive treatment with enfortumab vedotin (EV)
Inclusion Criteria: * Written informed consent by and HIPAA authorization for release of personal health information obtained from the research participant. * Able to speak and read English to a sufficient level of fluency to provide informed consent and complete the study questionnaires. * Age ≥ 18 years at the time of consent. * ECOG Performance Status of ≤ 3 within 28 days prior to consent. * Histological or cytologically confirmed urothelial carcinoma. * Patients must be planned to start systemic therapy with enfortumab vedotin * At time of enrollment, patients must be planned to start en…
Non-invasive nerve conduction studies (NCS) offer an objective, quantitative approach to assess peripheral nerve function, particularly in sensory fibers, which are most commonly affected in chemotherapy-induced peripheral neuropathy/CIPN
To evaluate the incidence and severity of chemotherapy-induced peripheral neuropathy (CIPN) in participants receiving enfortumab vedotin, we will collect non-therapeutic, participant-reported outcomes